经导管主动脉瓣置换术后瓣膜功能障碍的再次TAVR治疗
Redo-TAVR注册研究纳入37个中心共212例再次TAVR患者,占所有TAVR的0.33%。再次TAVR指征多为反流或混合性狭窄-反流,器械成功率达85.1%,围术期并发症低,症状改善显著,1年生存率在早期和晚期功能障碍组分别为83.6%和88.3%。
要点
- 再次TAVR在选择的TAVR后瓣膜功能障碍患者中安全有效。
- 器械成功率为85.1%,主要失败原因为残余高跨瓣压差和反流。
- 围术期并发症率低,无死亡,症状改善显著。
核心结论
- 对于选择的TAVR后瓣膜功能障碍患者,再次TAVR是相对安全和有效的选择。
研究设计与样本
- Redo-TAVR注册研究收集了37个中心连续接受再次TAVR的患者数据。
- 共识别212例再次TAVR手术,占63876例TAVR手术的0.33%。
- 患者分为可能TAVR失败(初次TAVR后1年内)和可能THV失败(初次TAVR后超过1年)。
主要发现
- 再次TAVR距初次手术时间在早期组为68(38-154)天,晚期组为5(3-6)年。
- 再次TAVR指征为THV狭窄在早期组12例(16.2%)和晚期组51例(37.0%)(p=0.002),反流或混合狭窄-反流在早期组62例(83.8%)和晚期组86例(62.3%)(p=0.028)。
- 器械成功(VARC-2标准)180例(85.1%),失败主要归因于残余高跨瓣压差(14.1%)或反流(8.9%)。
- 30天和1年随访残余跨瓣压差分别为12.6±7.5 mmHg和12.9±9.0 mmHg,瓣口面积分别为1.63±0.61 cm2和1.51±0.57 cm2,反流≤轻度分别为91%和91%。
- 围术期并发症率低:卒中3例(1.4%),瓣膜位置异常7例(3.3%),冠状动脉阻塞2例(0.9%),新永久起搏器20例(9.6%),无死亡。
临床怎么用
- 再次TAVR可作为选择的TAVR后瓣膜功能障碍患者的治疗策略。
- 需关注残余高跨瓣压差和反流等器械失败原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) use is increasing in patients with longer life expectancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited. Redo-TAVR may play a key strategy in treating patients in whom THVs fail. OBJECTIVES: The authors sought to examine outcomes following redo-TAVR. METHODS: The Redo-TAVR registry collected data on consecutive patients who underwent redo-TAVR at 37 centers. Patients were classified as probable TAVR failure or probable THV failure if they presented within or beyond 1 year of their index TAVR, respectively. RESULTS: Among 63,876 TAVR procedures, 212 consecutive redo-TAVR procedures were identified (0.33%): 74 within and 138 beyond 1 year of the initial procedure. For these 2 groups, TAVR-to-redo-TAVR time was 68 (38 to 154) days and 5 (3 to 6) years. The indication for redo-TAVR was THV stenosis in 12 (16.2%) and 51 (37.0%) (p = 0.002) and regurgitation or combined stenosis-regurgitation in 62 (83.8%) and 86 (62.3%) (p = 0.028), respectively. Device success using VARC-2 criteria was achieved in 180 patients (85.1%); most failures were attributable to high residual gradients (14.1%) or regurgitation (8.9%). At 30-day and 1-year follow-up, residual gradients were 12.6 ± 7.5 mm Hg and 12.9 ± 9.0 mm Hg; valve area 1.63 ± 0.61 cm2 and 1.51 ± 0.57 cm2; and regurgitation ≤mild in 91% and 91%, respectively. Peri-procedural complication rates were low (3 stroke [1.4%], 7 valve malposition [3.3%], 2 coronary obstruction [0.9%], 20 new permanent pacemaker [9.6%], no mortality), and symptomatic improvement was substantial. Survival at 30 days was 94.6% and 98.5% (p = 0.101) and 83.6% and 88.3% (p = 0.335) at 1 year for patients presenting with early and late valve dysfunction, respectively. CONCLUSIONS: Redo-TAVR is a relatively safe and effective option for selected patients with valve dysfunction after TAVR. These results are important for applicability of TAVR in patients with long life expectancy in whom THV durability may be a concern.
引用
- Landes U, Webb JG, De Backer O, et al. Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. J Am Coll Cardiol. 2020. PMID: 32327098. doi:10.1016/j.jacc.2020.02.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。